Sanara MedTech, Inc SMTI 深 滬
已收盤 07-18 16:00:00 美东时间
26.31
-1.150
-4.19%
華盛通- 最 高28.36
- 今 開27.77
- 成交量 5.17万股
- 最 低 26.31
- 昨 收 27.46
- 總市值 2.34亿
- 52周最高 39.08
- 市盈率 靜 --
- 換手率 0.58%
- 52周最低 25.86
- 委 比 12.66%
- 總股本 888.79万
- 歷史最高 53.85
- 量 比 0.80
- 振 幅 7.47%
- 歷史最低 17.41
- 每 手 1
- 風險率 3.74%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Sanara MedTech to Report Second Quarter 2025 Financial Results on August 13, 2025
Sanara MedTech Inc. will report its Q2 2025 financial results on August 13, 2025, before U.S. markets open. A conference call and webcast at 8:00 a.m. ET will discuss the results, with replay options available. The company, specializing in medical technologies for surgical, chronic wound, and skin markets, markets and develops products like CellerateRX® and FORTIFY TRG® to improve clinical outcomes and lower healthcare costs, and pursues strategi...
07-15 20:05
Sanara MedTech Launches Pilot Program Through Tissue Health Plus To Advance Value-Based Wound Care
Pilot program designed to provide real-world evidence in the use of Tissue Health Plus' technology platformFORT WORTH, TX, July 14, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or
07-15 04:07
Sanara MedTech Inc. Announces Launch of Tissue Health Plus Wound Care Provider Pilot Program
Sanara MedTech Inc. announced the launch of a pilot program through its subsidiary, Tissue Health Plus (THP), aimed at improving chronic wound care outcomes and reducing costs. The program, a first-of-its-kind value-based offering, involves a partnership with a wound care provider group serving six states. THP's technology platform serves as the group's operating system, integrating with their electronic medical records to streamline care process...
07-14 20:05
Sanara MedTech Updates Investor Presentation Online
An announcement from Sanara MedTech ( ($SMTI) ) is now available. On May 22, 20...
05-28 20:45
Sanara MedTech’s CAO Michael McNeil Announces Retirement
Sanara MedTech ( ($SMTI) ) has issued an update. On May 19, 2025, Michael D. Mc...
05-24 05:05
美股大行评级 | 潜在涨幅1281.22%！Cabaletta Bio获Guggenheim升目标价至25美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130057143861719040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Cabaletta Bio(CABA)"买入"评级，目标价从23美元升至25美元</p> <p>• 瑞穗：维持Tectonic Therapeutic(TECX)"跑赢大市"评级，目标价从51美元
05-16 08:43
HC Wainwright & Co. Maintains Buy on Sanara MedTech, Raises Price Target to $53
HC Wainwright & Co. analyst Yi Chen maintains Sanara MedTech (NASDAQ:SMTI) with a Buy and raises the price target from $51 to $53.
05-15 19:36
Sanara MedTech Q1 EPS $(0.41) Beats $(0.48) Estimate, Sales $23.43M Inline
Sanara MedTech (NASDAQ:SMTI) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.48) by 14.58 percent. This is a 95.24 percent decrease over losses of $(0.21) per share from
05-14 19:06
Earnings Scheduled For May 14, 2025
Companies Reporting Before The Bell • Cellebrite DI (NASDAQ:CLBT) is expected t...
05-14 16:32
美股大行评级 | 潜在涨幅706.45%！Guggenheim上调InflaRx目标价至10美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1111936502896275457.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持InflaRx(IFRX)"买入"评级，目标价从7美元升至10美元</p> <p>• Oppenheimer：维持Corvus Pharma(CRVS)"跑赢大市"评级，目标价从14美元升至15美
03-27 09:48
